Search research articles
Contact Us
Filters
Showing results (151-160 of 251) with videos related to
Page
of 26
Sort By:
Future Oncology (London, England)
|
March 14, 2020
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
Pau Montesinos, Benjamin M Beckermann, Olivier Catalani, et al.
Blood
|
June 19, 2010
The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome
Thomas Prebet, Anne-Catherine Lhoumeau, Christine Arnoulet, et al.
Blood Advances
|
September 15, 2021
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
Raynier Devillier, Edouard Forcade, Alice Garnier, et al.
Haematologica
|
February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Thomas Pabst, Norbert Vey, Lionel Adès, et al.
British Journal of Haematology
|
February 22, 2011
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial
Carine Domenech, Xavier Thomas, Sylvie Chabaud, et al.
Cancer Immunology Research
|
September 20, 2024
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Anne-Charlotte Le Floch, Caroline Imbert, Nicolas Boucherit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 10, 2013
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease
Raynier Devillier, Sabine Fürst, Jean El-Cheikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience
Eric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 16, 2018
HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison
Raynier Devillier, Faezeh Legrand, Jérôme Rey, et al.
American Journal of Hematology
|
October 11, 2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
Raynier Devillier, Sabine Fürst, Roberto Crocchiolo, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 251) with videos related to
Sort By:
Page
of 26
Future Oncology (London, England)
|
March 14, 2020
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
Pau Montesinos, Benjamin M Beckermann, Olivier Catalani, et al.
Blood
|
June 19, 2010
The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome
Thomas Prebet, Anne-Catherine Lhoumeau, Christine Arnoulet, et al.
Blood Advances
|
September 15, 2021
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
Raynier Devillier, Edouard Forcade, Alice Garnier, et al.
Haematologica
|
February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Thomas Pabst, Norbert Vey, Lionel Adès, et al.
British Journal of Haematology
|
February 22, 2011
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial
Carine Domenech, Xavier Thomas, Sylvie Chabaud, et al.
Cancer Immunology Research
|
September 20, 2024
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis
Anne-Charlotte Le Floch, Caroline Imbert, Nicolas Boucherit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 10, 2013
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease
Raynier Devillier, Sabine Fürst, Jean El-Cheikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2005
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience
Eric Jourdan, Jean-Michel Boiron, Nicole Dastugue, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 16, 2018
HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison
Raynier Devillier, Faezeh Legrand, Jérôme Rey, et al.
American Journal of Hematology
|
October 11, 2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
Raynier Devillier, Sabine Fürst, Roberto Crocchiolo, et al.
Page
of 26